Traders bought shares of Celgene Corp. (NASDAQ:CELG) on weakness during trading hours on Thursday. $112.27 million flowed into the stock on the tick-up and $90.44 million flowed out of the stock on the tick-down, for a money net flow of $21.83 million into the stock. Of all equities tracked, Celgene Corp. had the 12th highest net in-flow for the day. Celgene Corp. traded down ($0.34) for the day and closed at $101.42

CELG has been the topic of several recent analyst reports. Leerink Swann reaffirmed a “market perform” rating on shares of Celgene Corp. in a report on Monday, May 2nd. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corp. in a report on Wednesday, June 8th. BTIG Research reissued a “buy” rating and set a $140.00 price objective on shares of Celgene Corp. in a report on Tuesday, May 24th. Zacks Investment Research cut Celgene Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, May 3rd. Finally, Vetr cut Celgene Corp. from a “buy” rating to a “hold” rating and set a $106.06 price objective on the stock. in a report on Wednesday, July 6th. Five research analysts have rated the stock with a hold rating and twenty-three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $139.12.

The stock has a market capitalization of $79.67 billion and a P/E ratio of 50.02. The company’s 50 day moving average price is $102.24 and its 200-day moving average price is $103.56.

Celgene Corp. (NASDAQ:CELG) last announced its earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.03. During the same period last year, the business posted $1.07 EPS. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.59 billion. The firm’s revenue was up 20.7% compared to the same quarter last year. On average, equities analysts forecast that Celgene Corp. will post $5.68 EPS for the current year.

In other Celgene Corp. news, insider Robert J. Hugin sold 75,000 shares of the stock in a transaction on Monday, June 20th. The stock was sold at an average price of $100.16, for a total transaction of $7,512,000.00. Following the sale, the insider now owns 1,122,201 shares of the company’s stock, valued at approximately $112,399,652.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Several hedge funds have bought and sold shares of CELG. Synovus Financial Corp boosted its stake in Celgene Corp. by 16.6% in the fourth quarter. Synovus Financial Corp now owns 8,571 shares of the biopharmaceutical company’s stock worth $1,027,000 after buying an additional 1,222 shares during the last quarter. WMS Partners LLC boosted its stake in Celgene Corp. by 20.9% in the fourth quarter. WMS Partners LLC now owns 8,669 shares of the biopharmaceutical company’s stock worth $1,038,000 after buying an additional 1,500 shares during the last quarter. Genesee Valley Trust Co. boosted its stake in Celgene Corp. by 4.2% in the fourth quarter. Genesee Valley Trust Co. now owns 8,820 shares of the biopharmaceutical company’s stock worth $1,056,000 after buying an additional 359 shares during the last quarter. Investment Management of Virginia LLC boosted its stake in Celgene Corp. by 63.0% in the fourth quarter. Investment Management of Virginia LLC now owns 9,043 shares of the biopharmaceutical company’s stock worth $1,083,000 after buying an additional 3,495 shares during the last quarter. Finally, NBT Bank N A NY boosted its stake in Celgene Corp. by 0.3% in the fourth quarter. NBT Bank N A NY now owns 9,248 shares of the biopharmaceutical company’s stock worth $1,107,000 after buying an additional 30 shares during the last quarter.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.